

# Opdualag (nivolumab and relatlimab-rmbw)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Opdualag (nivolumab and relatlimab-rmbw) intravenous solution

## **APPROVAL CRITERIA**

Requests for Opdualag may be approved if the following criteria are met:

- I. Individual is 12 years of age or older and weighing at least 40 kg (Label; Tawbi HA et.al. 2022, NCCN 1):**AND**
- II. Individual has a diagnosis of unresectable or metastatic (Stage III or IV) melanoma;  
**AND**
- III. Individual has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 or a Lansky performance score  $\geq$  80% for minors (12 to 17 years of age).

Requests for Opdualag may not be approved for the following criteria:

- I. If individual had uveal melanoma; **OR**
- II. If individual has active brain metastases or leptomeningeal metastases; **OR**
- III. When the above criteria are not met, and for all other indications.

## **Key References:**

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2023. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: July 8, 2023
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2023; Updated periodically.
5. NCCN Clinical Practice Guidelines in Oncology™. © 2023 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on July 8, 2023.
  - a. Melanoma: Cutaneous V2.2023. Revised March 10, 2023.
6. Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N. Engl J Med.2022;386(1):24-34. Accessed July 8, 2023

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.